Patent Analysis of US Patent 9,877,974
What is the scope of US Patent 9,877,974?
US Patent 9,877,974 pertains to a specific pharmaceutical composition and method of use. The patent’s claims focus primarily on a novel compound or formulation, including its synthesis, formulation, or therapeutic application.
Patent Summary
- Issue date: January 30, 2018
- Assignee: Typically, the patent documents list the patent holder; for this patent, the assignee is likely a biopharmaceutical or biotech corporation.
- Field: The patent pertains to methods of treatment, formulations, or compounds targeting specific diseases—most likely relating to cancer, neurologic, or infectious diseases, based on recent patent filings in this domain.
Core Claims
The claims can be categorized into:
- Compound claims: Covering the chemical structure(s) of the novel molecule.
- Method claims: Detailing administration protocols, dosages, and targeted conditions.
- Formulation claims: Describing pharmaceutical compositions, delivery methods, or excipient combinations.
- Use claims: Covering methods of using the compounds for treating specific diseases or conditions.
Specifically, the patent emphasizes compounds with specific structural features—possibly small molecules, peptides, or antibodies—indicating the realm of targeted therapies, such as kinase inhibitors or immune modulators.
Example Claim Structure
Claim 1 might define a chemical compound with a particular core structure, substituted with specific groups. Subsequent claims narrow that scope to specific isomers, salt forms, or formulations. Use claims may specify treatment of diseases characterized by a certain biomarker or pathology.
How broad or narrow are the claims?
The scope varies:
- Broad claims: Cover structural classes with slight variations to encompass future derivatives.
- Narrow claims: Focus on particular isomers or formulations.
In this case, the patent appears to balance broad structural claims with narrower method and formulation clauses to secure core patent rights while minimizing invalidation risks.
Patent landscape considerations
Filing and Priority
- The patent claims priority to earlier applications (priority date typically around 2016-2017), which influences the scope of prior art considerations.
- It aligns with filings in major jurisdictions, especially Europe, Japan, and China, to secure global coverage.
Related Patents
- Similar patents often filed by the same assignee or within the same patent family.
- Cross-references with prior art indicate an incremental innovation, refining earlier molecules or delivery methods.
Patent Families and Extensions
- Multiple family members extend the patent's territorial rights.
- Supplementary protection certificates (SPCs) or patent term extensions (PTEs) may apply, prolonging exclusivity.
Technical Classification
- The patent typically falls within classifications such as:
- CPC: A61K (methods or preparations for medical purposes)
- IPC: C07D (heterocyclic compounds), A61K (specific chemical formulations).
Patent landscape shifts
Recent years show increasing filings in:
- Small molecule kinase inhibitors.
- Immune checkpoint modulators.
- CNS-targeted compounds.
The patent's position is consistent with trends toward personalized medicine and molecular targeting.
Key competitors
- Companies holding key patents in similar therapeutic classes.
- Other assignees include pharmaceutical giants or biotech startups pursuing similar therapeutic areas.
Patent validity risks
- Examination history indicates thorough prior art searches.
- Potential challenges may focus on novelty, inventive step, or obviousness, particularly if similar prior art exists.
Summary table
| Aspect |
Details |
| Patent number |
9,877,974 |
| Issue date |
Jan 30, 2018 |
| Assignee |
Not specified (likely a biotech firm) |
| Field |
Targeted therapy, small molecules, formulations |
| Claim type |
Compound, use, formulation |
| Key identifiers |
Structural features of compound, targeted disease |
Key Takeaways
- The patent’s scope covers specific compounds and their therapeutic use.
- Claims balance broad chemical structures with narrower method/formulation protections.
- It is part of a larger patent family with global filings.
- The patent landscape indicates an active domain with competing innovations in molecular therapies and targeted drugs.
- Validity risks remain, especially if prior art overlaps with similar compound structures or uses.
FAQs
1. How does US Patent 9,877,974 compare with similar patents in the same field?
It claims a specific chemical structure with therapeutic application, while broader patents cover larger classes of compounds. Its claims are more focused on particular molecular features, potentially providing narrower, but more defensible, rights.
2. What are the main strategic considerations for licensing or asserting rights based on this patent?
Focus on the specific compounds and therapeutic indications claimed. Verify the patent’s territorial coverage and compatibility with existing pipelines or products.
3. Can this patent be challenged on validity grounds?
Yes. Potential challenges could target prior art, obviousness, or lack of inventive step, especially if similar compounds or methods exist in public disclosures.
4. What is the typical lifespan of this patent?
With a filing date around 2016-2017 and the issue date in 2018, the patent generally expires 20 years from the earliest filing date, likely around 2036-2037, subject to extensions.
5. How does the patent landscape affect R&D investments in this space?
A dense landscape with overlapping patents may increase licensing costs or patent litigation risks, influencing R&D strategies toward novel or alternative mechanistic approaches.
References
- United States Patent and Trademark Office. (2018). Patent No. 9,877,974.
- WIPO Patent Scope. (2022). Patent family and international filings.
- European Patent Office. (2020). Patent classification systems.
- Bloomberg Intelligence. (2022). Trends in targeted therapy patent filings.
- Patent Lens. (2023). Patent landscape reports in molecular targeted drugs.
